1458 GMT - Novo Nordisk's trial results for its new CagriSema weight-loss drug failed to impress, Stifel analyst Eric Le Berrigaud writes. This was the second phase 3 trial to evaluate CagriSema, this time in obese patients with diabetes. The type 2 diabetes population has a higher unmet need and CagriSema was expected to show a greater benefit in diabetic patients than in those without the disease. The results therefore remove a clear upside scenario, he says. "CagriSema does not seem to add a lot versus Eli Lilly's Tirzepatide either." Shares fall 3.2%. (dominic.chopping@wsj.com)
(END) Dow Jones Newswires
March 11, 2025 10:58 ET (14:58 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.